The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Has the era of untreatable infections arrived?
Abstract
Antibiotic resistance is a major public health concern, with fears expressed that we shortly will run out of antibiotics. In reality, the picture is more mixed, improving against some pathogens but worsening against others. Against methicillin-resistant Staphylococcus aureus (MRSA)--the highest profile pathogen--the range of treatment options is expanding, with daptomycin, linezolid and tigecycline all launched, and telavancin, ceftobiprole, ceftaroline and dalbavancin anticipated. There is a greater problem with enterococci, especially if, as in endocarditis, bactericidal activity is needed and the isolate has high-level aminoglycoside resistance; nevertheless, daptomycin, telavancin and razupenem all offer cidal potential. Against Enterobacteriaceae, the rapid and disturbing spread of extended-spectrum beta-lactamases, AmpC enzymes and quinolone resistance is forcing increased reliance on carbapenems, with resistance to these slowly accumulating via the spread of metallo-, KPC and OXA-48 beta-lactamases. Future options overcoming some of these mechanisms include various novel beta-lactamase-inhibitor combinations, but none of these overcomes all the carbapenemase types now circulating. Multiresistance that includes carbapenems is much commoner in non-fermenters than in the Enterobacteriaceae, depending mostly on OXA carbapenemases in Acinetobacter baumannii and on combinations of chromosomal mutation in Pseudomonas aeruginosa. No agent in advanced development has much to offer here, though there is interest in modified, less-toxic, polymyxin derivatives and in the siderophore monobactam BAL30072, which has impressive activity against A. baumannii and members of the Burkholderia cepacia complex. A final and surprising problem is Neisseria gonorrhoeae, where each good oral agent has been eroded in turn and where there is now little in reserve behind the oral oxyimino cephalosporins, to which low-level resistance is emerging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,491
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,499
Whitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., Lynfield, R., Reingold, A., Cieslak, P. R., Pilishvili, T., Jackson, D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022823 · Cited by 2,228
Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H. W., Scheld, W. M., Bartlett, J. G., Edwards, J., & the Infectious Diseases Society of America (2008) · Clinical Infectious Diseases · doi:10.1086/524891 · Cited by 1,642
High Frequency of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Lung Infection
Oliver, A., Cantón, R., Campo, P., Baquero, F., & Blázquez, J. (2000) · Science · doi:10.1126/science.288.5469.1251 · Cited by 1,465
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?
Livermore, D. M. (2002) · Clinical Infectious Diseases · doi:10.1086/338782 · Cited by 1,453
Self-citationCTX-M: changing the face of ESBLs in Europe
Livermore, D. M., Canton, R., Gniadkowski, M., Nordmann, P., Rossolini, G. M., Arlet, G., Ayala, J., Coque, T. M., Kern-Zdanowicz, I., Luzzaro, F., et al. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl483 · Cited by 927
Self-citationAntimicrobial resistance in developing countries. Part I: recent trends and current status
Okeke, I. N., Laxminarayan, R., Bhutta, Z. A., Duse, A. G., Jenkins, P., O'Brien, T. F., Pablos-Mendez, A., & Klugman, K. P. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70189-4 · Cited by 851
Cited by
Kumarasamy, K. K., Toleman, M. A., Walsh, T. R., Bagaria, J., Butt, F., Balakrishnan, R., Chaudhary, U., Doumith, M., Giske, C. G., Irfan, S., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70143-2 · Cited by 2,922
Self-citationAntibiotic resistance is ancient
D’Costa, V. M., King, C. E., Kalan, L., Morar, M., Sung, W. W. L., Schwarz, C., Froese, D., Zazula, G., Calmels, F., Debruyne, R., et al. (2011) · Nature · doi:10.1038/nature10388 · Cited by 2,720
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
Walsh, T. R., Weeks, J., Livermore, D. M., & Toleman, M. A. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70059-7 · Cited by 1,250
Self-citationEnvironmental factors influencing the development and spread of antibiotic resistance
Bengtsson-Palme, J., Kristiansson, E., & Larsson, D. G. J. (2018) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux053 · Cited by 1,167
Mechanisms of bacterial persistence during stress and antibiotic exposure
Harms, A., Maisonneuve, E., & Gerdes, K. (2016) · Science · doi:10.1126/science.aaf4268 · Cited by 919
Peritoneal Dialysis-Related Infections Recommendations: 2010 Update
Li, P. K.-T., Szeto, C. C., Piraino, B., Bernardini, J., Figueiredo, A. E., Gupta, A., Johnson, D. W., Kuijper, E. J., Lye, W.-C., Salzer, W., et al. (2010) · Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis · doi:10.3747/pdi.2010.00049 · Cited by 887
EUCAST expert rules in antimicrobial susceptibility testing
Leclercq, R., Cantón, R., Brown, D. F. J., Giske, C. G., Heisig, P., MacGowan, A. P., Mouton, J. W., Nordmann, P., Rodloff, A. C., Rossolini, G. M., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03703.x · Cited by 683
The increasing threat of Pseudomonas aeruginosa high-risk clones
Oliver, A., Mulet, X., López-Causapé, C., & Juan, C. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.002 · Cited by 644
The Evolution of Fungicide Resistance
Lucas, J. A., Hawkins, N. J., & Fraaije, B. A. (2015) · Advances in Applied Microbiology · doi:10.1016/bs.aambs.2014.09.001 · Cited by 638
Nationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China
Zhang, R., Liu, L., Zhou, H., Chan, E. W., Li, J., Fang, Y., Li, Y., Liao, K., & Chen, S. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.04.032 · Cited by 542
Khan, A. U., Maryam, L., & Zarrilli, R. (2017) · BMC Microbiology · doi:10.1186/s12866-017-1012-8 · Cited by 512
Emerging carbapenemases: a global perspective
Walsh, T. R. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(10)70004-2 · Cited by 506
Actinomycetes: Still a source of novel antibiotics
Genilloud, O. (2017) · Natural Product Reports · doi:10.1039/c7np00026j · Cited by 465
Zarkotou, O., Pournaras, S., Tselioti, P., Dragoumanos, V., Pitiriga, V., Ranellou, K., Prekates, A., Themeli-Digalaki, K., & Tsakris, A. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03514.x · Cited by 438
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
Zhanel, G. G., Lawson, C. D., Adam, H., Schweizer, F., Zelenitsky, S., Lagacé-Wiens, P. R. S., Denisuik, A., Rubinstein, E., Gin, A. S., Hoban, D. J., et al. (2013) · Drugs · doi:10.1007/s40265-013-0013-7 · Cited by 433
Bush, K., & Fisher, J. F. (2011) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090110-102911 · Cited by 419
Chen, B., Yang, Y., Liang, X., Yu, K., Zhang, T., & Li, X. (2013) · Environmental Science & Technology · doi:10.1021/es403818e · Cited by 415
Multidrug Efflux Pumps in Staphylococcus aureus: an Update
Costa, S. S., Viveiros, M., Amaral, L., & Couto, I. (2013) · The Open Microbiology Journal · doi:10.2174/1874285801307010059 · Cited by 409
Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae
Bush, K. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.09.006 · Cited by 398
Huang, L., Xuan, Y., Koide, Y., Zhiyentayev, T., Tanaka, M., & Hamblin, M. R. (2012) · Lasers in Surgery and Medicine · doi:10.1002/lsm.22045 · Cited by 394
Hannan, T. J., Totsika, M., Mansfield, K. J., Moore, K. H., Schembri, M. A., & Hultgren, S. J. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2012.00339.x · Cited by 367
Capone, A., Giannella, M., Fortini, D., Giordano, A., Meledandri, M., Ballardini, M., Venditti, M., Bordi, E., Capozzi, D., Balice, M. P., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12070 · Cited by 346
Nathwani, D., Raman, G., Sulham, K., Gavaghan, M., & Menon, V. (2014) · Antimicrobial Resistance and Infection Control · doi:10.1186/2047-2994-3-32 · Cited by 344
Crielaard, W., Zaura, E., Schuller, A. A., Huse, S. M., Montijn, R. C., & Keijser, B. J. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-22 · Cited by 320
Bacterial persisters: molecular mechanisms and therapeutic development
Niu, H., Gu, J., & Zhang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01866-5 · Cited by 310
Emergence of Klebsiella pneumoniae Carbapenemase-Producing Bacteria
Arnold, R. S., Thom, K. A., Sharma, S., Phillips, M., Kristie Johnson, J., & Morgan, D. J. (2011) · Southern Medical Journal · doi:10.1097/smj.0b013e3181fd7d5a · Cited by 307
Spread of OXA-48-Encoding Plasmid in Turkey and Beyond
Carrër, A., Poirel, L., Yilmaz, M., Akan, O. A., Feriha, C., Cuzon, G., Matar, G., Honderlick, P., & Nordmann, P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01312-09 · Cited by 273
Antibiotics in the clinical pipeline in 2011
Butler, M. S., & Cooper, M. A. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.44 · Cited by 272
Lood, R., Winer, B. Y., Pelzek, A. J., Diez-Martinez, R., Thandar, M., Euler, C. W., Schuch, R., & Fischetti, V. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04641-14 · Cited by 272
The global need for effective antibiotics: challenges and recent advances
Högberg, L. D., Heddini, A., & Cars, O. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.08.002 · Cited by 264
Eliakim-Raz, N., Yahav, D., Paul, M., & Leibovici, L. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt177 · Cited by 153
Efflux inhibition by selective serotonin reuptake inhibitors in Escherichia coli
Bohnert, J. A., Szymaniak-Vits, M., Schuster, S., & Kern, W. V. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr258 · Cited by 114
Manohar, P., Shanthini, T., Ayyanar, R., Bozdogan, B., Wilson, A., Tamhankar, A. J., Nachimuthu, R., & Lopes, B. S. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000508 · Cited by 104
Escalating antimicrobial resistance among Enterobacteriaceae: Focus on carbapenemases
Lynch, J. P., Clark, N. M., & Zhanel, G. G. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1904891 · Cited by 58
Docquier, J.-D., Benvenuti, M., Calderone, V., Stoczko, M., Menciassi, N., Rossolini, G. M., & Mangani, S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00409-10 · Cited by 51
Metadata
- Authors
- Livermore, D. M.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08-12
- Volume
- 64
- Issue
- Supplement 1
- Pages
- i29-i36
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2153732335
- Cited by
- 620
- References
- 53
- FWCI
- 27.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.